Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, announced that the U.S. Food and Drug Administration (FDA) approved its noninvasive colorectal cancer (CRC) screening test, ColoSense. ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at typical average risk for developing CRC.
Contact Andrew at:
[email protected]